Feasibility of out-patient autologous stem cell transplantation for malignant haematologic disorders

Introduction: High-dose chemotherapy with autologous stem cell support is utilized for the treatment of a variety of malignancies including non-Hodgkin's lymphoma, Hodgkin's lymphoma, and acute leukemias. The aim of this study was to explore the feasibility and safety of performing autolog...

Full description

Saved in:

Bibliographic Details
Published in:	Bone marrow transplantation (Basingstoke) Vol. 43; no. S1; p. S380
Main Authors:	Ghavamzadeh, A, Allahyari, A, Alimoghaddam, K, Karimi, A, Aboulhasani, R, Manookian, A, Asadi, M, Shamshiri, A.R
Format:	Journal Article
Language:	English
Published:	Nature Publishing Group 01-03-2009
Subjects:	Care and treatment Hodgkin's disease Leukemia Non-Hodgkin's lymphomas Patient outcomes Stem cells Transplantation Iran
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Introduction: High-dose chemotherapy with autologous stem cell support is utilized for the treatment of a variety of malignancies including non-Hodgkin's lymphoma, Hodgkin's lymphoma, and acute leukemias. The aim of this study was to explore the feasibility and safety of performing autologous stem cell transplantation (ASCT) on an out-patient basis. Material and Methods: Total of 8 patients affected by malignant hematologic disorders(4 cases of HL, 2 cases of NHL, 2 cases of AML) with median age of 25 y (range :16-41 y) and in complete remission and without medical problem were selected. They received conditioning regimen (CEAM for NHL and HL, Busulfan and Etoposide for AML) and stem cell infusion in hospital. The day after SCT, patients were discharged and followed by outpatient SCT team; include a general physician, staff nurse and care giver during their neutropenic period, and to be rehospitalized in the case of febrile neutropenia, after sepsis workup and performing chest x-ray, they were received the first dose of antibiotic in hospital and treatment continued in their home. Results: Median time for WBC recovery was11 days (range: 8-13 days), median time for PLT recovery was 15 days (range: 11-66 days), median number of transfused single donor PLT was 2.5 units (range: 1-9 unit). Mucusitis grade 3 was seen in 2 patients, median duration of neutropenic fever was 6 days (range: 0-10 days), 3 patients was rehospitalized because of the neutropenic fever, median duration of rehospitalization in these patients was 5 days, median follow up of patients was 130 days (range: 20-200 days), all patients were alive and in complete remission. Conclusion: Results show that out-patient autolgous SCT in malignant hematologic disorders (HL, NHL, and AML) is feasible and its complication is manageable.
ISSN:	0268-3369